Business
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizationsRepeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titersACI-7104.056 is well tolerated with no safety issues reported to
About this update from Ac Immune Sa
[{"type":"image","alt":"AC Immune SA","displaySize":"","headline":null,"caption":"AC Immune SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":240,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/3c2df2034a46edd1abf458c36df78606"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ppRSnZQxE6Y9H9qhIOFsHg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c2df2034a46edd1abf458c36df78606","width":240,"height":75}},"lazy":false},{"type":"text","content":"AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease","length":135,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) antibody levels on average over 20-fold higher than placebo after 4 immunizations","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Repeated immunizations amplify the anti-a-syn antibody response, supporting boostability and the potential to further increase antibody titers","length":142,"tagName":"p"}]},{"val":[{"type":"text","content":"ACI-7104.056 is well tolerated with no safety issues reported to date","length":69,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":369,"olType":false},{"type":"text","content":"Lausanne, Switzerland, April 2, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, its wholly owned anti-alpha-synuclein (a-syn) active immunotherapy candidate, for the treatment of patients with early Parkinson’s disease (PD).","length":460,"tagName":"p"},{"type":"text","content":"Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We continue to be encouraged by the data emerging from the Phase 2 VacSYn trial of ACI-7104.056 active immunotherapy in early Parkinson’s disease. These additional interim safety and immunogenicity data after 6 months of treatment underscore the good safety profile and reinforce the best-in-class characteristics of ACI-7104.056 for the treatment of Parkinson’s disease. We look forward to sharing further updates later ...